DEF: Amgen Sets 2026 Annual Meeting Date, Highlights 2025 Performance

Amgen Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on May 19, 2026, detailing strong 2025 performance in drug development, sales growth, and manufacturing investments.

Summary

• Amgen Inc. is holding its 2026 Annual Meeting of Stockholders virtually on May 19, 2026.
• The company reported strong execution in 2025, with 10% year-over-year revenue and sales growth.
• 18 products achieved record sales, and 14 products exceeded $1 billion in sales.
• Key clinical advancements include FDA approvals for IMDELLTRA, LUMAKRAS, and UPLIZNA, and progress in the MariTide Phase 3 program for obesity.
• Amgen announced significant manufacturing investments totaling $900 million in Ohio and $650 million in Puerto Rico to expand its U.S. biomanufacturing network.
• The company also invested $7 billion in R&D and $2 billion in capital expenditures in 2025, while reducing debt by $6 billion and returning $5 billion to stockholders via dividends.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively, highlighting strong financial performance, significant R&D and manufacturing investments, and successful pipeline progression, indicating robust operational execution and strategic focus.

Positives

• 10% year-over-year revenue and sales growth in 2025.
• 18 products achieved record sales.
• 14 products exceeded $1 billion in sales.
• 13 products delivered double-digit sales growth.
• Five important FDA regulatory approvals received in 2025, including for IMDELLTRA, LUMAKRAS, and UPLIZNA.
• Advancement of the MariTide Phase 3 program in obesity and obesity-related conditions.
• Repatha Phase 3 study showed significant reduction in major adverse CV events (25%) and heart attack risk (36%).
• Significant manufacturing investments: $1 billion in North Carolina (announced 2024), $900 million in Ohio, and $650 million in Puerto Rico in 2025.
• Reduced debt outstanding by $6 billion in 2025.
• Returned $5 billion of capital to stockholders in dividends, with a 6% increase in quarterly dividend per share.
• Strong engagement with stockholders, with approximately 59% of outstanding shares represented in outreach activities.

Negatives

• Patents for top-selling drugs Prolia and Xgeva expired in the U.S. in February 2025, leading to sales erosion.
• A $400 million intangible asset impairment charge in Q3 2025 related to Otezla psoriasis, tied to U.S. government price negotiations.
• Enbrel sales decreased significantly (30% year-over-year in Q3 2025) due to lower net selling prices and Medicare Part D redesign.
• Stock price decline following concerns about the tolerability of the MariTide weight-loss drug candidate.
• Stockholder proposal to require an independent Board Chairman, which the Board recommends voting against.

Risks

• Continued negative impact from lower net selling prices and pricing headwinds across the portfolio.
• Potential sales declines for Prolia and Xgeva due to biosimilar competition.
• Concerns about the tolerability of the MariTide weight-loss drug candidate.
• Potential for government investigations, litigation, and product liability claims.
• Challenges in manufacturing products and potential supply limits.
• Competition from other products, including biosimilars.
• Risks associated with collaborations and acquisitions not being successful.
• Cybersecurity risks and potential information security breaches.
• Stock price volatility.
• Failure to achieve sustainability objectives could negatively affect business and operations.
• Global economic conditions and geopolitical relations may magnify risks.

Future Outlook

Amgen's strategy focuses on developing innovative medicines, advancing its pipeline, and expanding manufacturing capabilities. The company anticipates continued growth driven by its product portfolio and pipeline advancements, while managing pricing pressures and patent expirations through ongoing innovation and strategic investments.

Management Comments

• "For more than 45 years, Amgen's mission has been to serve patients."
• "Our innovative and biosimilar medicine portfolios are serving millions of patients globally, and therapies advancing through our pipeline address serious illnesses and unmet medical needs of a rapidly aging global population."
• "2025 was another year of strong execution, with 10% year-over-year revenue and sales growth, 18 of our products achieving record sales, 14 products exceeding $1 billion in sales, and 13 products delivering double-digit sales growth."
• "We also delivered on an ambitious research and development program agenda, including receiving five important U.S. Food and Drug Administration (FDA) regulatory approvals and advancing the MariTide (maridebart cafraglutide) Phase 3 program in obesity and obesity-related conditions."
• "These expansions reinforce our long-standing commitment to U.S.-based biomanufacturing and are designed to enhance the resilience and flexibility of our global supply network."
• "We plan to continue this valuable dialogue with our investors in the coming year."

Industry Context

StockSavvy.ai notes that Amgen's performance in 2025, particularly its revenue growth and pipeline advancements, aligns with broader industry trends of innovation in biotechnology and the increasing importance of addressing serious illnesses. The company's significant investments in manufacturing and R&D reflect a strategic focus on long-term growth and resilience, common among leading biopharmaceutical firms navigating complex regulatory and market landscapes.

Comparison to Industry Standards

• Amgen's revenue growth of 10% in 2025 is strong compared to the average growth rates seen in the biotechnology and pharmaceutical sectors, which can vary significantly based on product cycles and market conditions.
• The company's investment of $7 billion in R&D in 2025 is substantial and aligns with industry leaders who prioritize innovation to maintain a competitive edge and address unmet medical needs.
• The $2 billion in capital expenditures for manufacturing expansion demonstrates a commitment to scaling operations, a critical factor for companies aiming to meet global demand for complex biologic medicines, a trend seen across major pharmaceutical players.
• Amgen's focus on a diversified pipeline with multiple therapeutic areas (General Medicine, Oncology, Inflammation, Rare Disease) is a standard practice for large biopharma companies seeking to mitigate risk and capture value across different disease segments.

Corporate Governance

Related Party Transactions

• Dr. Leandro Grimaldi, son-in-law of executive officer Nancy A. Grygiel, is employed as Business Performance Director. His 2025 compensation included $240,000 base salary, $78,810 incentive award, and $54,000 in equity grants. This transaction was approved by the Compensation and Management Development Committee in 2021 prior to his hiring.

Stakeholder Impact

• Shareholders: The company's strong financial performance, dividend increases, and strategic investments are intended to enhance shareholder value. The advisory vote on executive compensation and the stockholder proposal on board structure directly involve shareholder input.
• Employees: Investments in workforce transformation, AI training, and apprenticeship programs aim to enhance employee skills and development. The company also offers competitive benefits and a focus on a positive work environment.
• Patients: Amgen's mission to serve patients is central, with advancements in its pipeline addressing serious illnesses and unmet medical needs. Patient assistance programs and efforts to improve access to medicines are highlighted.
• Communities: The Amgen Foundation supports science education and community initiatives, with employees volunteering over 24,000 hours in 2025. Disaster relief grants were also provided.

Next Steps

• Attend the 2026 Annual Meeting of Stockholders on May 19, 2026.
• Vote on the election of 12 directors, advisory approval of executive compensation, ratification of independent auditors, and a stockholder proposal.
• Continue to monitor Amgen's pipeline development and commercial performance.

Key Dates

Recommendation

Amgen demonstrates strong operational execution and pipeline progress, with solid financial results and strategic investments. However, the upcoming patent expirations for key drugs (Prolia, Xgeva) and pricing headwinds present significant near-term challenges that warrant a cautious approach. While the long-term outlook remains positive due to innovation, these factors suggest a 'hold' recommendation until the impact of biosimilar competition and pricing pressures becomes clearer.

Keywords

Amgen, Proxy Statement, Annual Meeting, Executive Compensation, Board of Directors, FDA Approvals, Clinical Trials, MariTide, Repatha, IMDELLTRA, LUMAKRAS, UPLIZNA, Manufacturing, R&D, Stockholder Proposal